June 20, 2024 C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development C-Path, a leader in forming collaborations that accelerate drug development, and Centogene N.V. (Nasdaq: CNTG)...
June 16, 2024-June 20, 2024 Join C-Path at DIA Global 2024 C-Path CEO Klaus Romero will be a panelist in two sessions at the upcoming...
June 12, 2024 C-Path’s Parkinson’s Consortium Supports Groundbreaking Research Utilizing Smartwatches to Monitor Disease Progression Critical Path Institute (C-Path) today announced a new publication on how the use of wearable technology...
June 12, 2024 C-Path’s AI Collaborations Accelerate Drug Development, Improve Lives Critical Path Institute (C-Path) today announced the publication of a new peer-reviewed paper in the journal Clinical and...
June 12, 2024 Using a smartwatch and smartphone to assess early Parkinson’s disease in the WATCH-PD study over 12 months Digital measures may provide objective, sensitive, real-world measures of disease progression in Parkinson’s disease (PD).
June 10, 2024 Advocate Sarah Dolan Brings a Patient Voice to FDA Committee Reviewing New Alzheimer’s Drug Donanemab On Monday, June 10, the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Drugs Advisory...
June 5, 2024 eCOA Masterclass #1: The Road to Best Practice Consensus: Electronic Migration and Implementation of PRO Measures Join the co-authors of the published article in Value in Health for a deep dive into existing and current best practices for the..
June 3, 2024-June 6, 2024 Connect with C-Path at BIO 2024: Join us on the path forward in drug development C-Path CEO Klaus Romero will be a panelist in two sessions at the upcoming BIO 2024 Conference. In two featured sessions...
May 30, 2024 C-Path Supports Gleason, ALS Community at IgNight ALS The C-Path team was incredibly humbled to be a part of IgNight ALS recently in Washington, D.C., honoring Steve Gleason and celebr
May 28, 2024 Accelerating healthcare innovation: the role of Artificial intelligence and digital health technologies in critical path institute’s public-private partnerships Artificial Intelligence (AI) and Digital Health Technologies (DHTs) are radically transforming drug development. The FDA and EMA..
